ESG206 study for active primary Sjögren's syndrome
Part of Immune system & allergy clinical trials.
This study tests an investigational drug called ESG206, which targets a protein on immune cells, to see if it can safely reduce symptoms of primary Sjögren's syndrome. It is for people whose Sjögren's is not caused by another disease and who have active symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with primary Sjögren's syndrome by a doctor using standard criteria.
- Your Sjögren's symptoms are currently active.
- You have not recently used strong immune-suppressing medications (your doctor can check this).
- You do not have another serious autoimmune disease, an active infection, or uncontrolled health problem.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is building a new model to help doctors treat primary Sjögren's syndrome using a combination of traditional Chinese medicine and Western medicine. It may help find better ways to manage your symptoms.
This study tests an investigational drug called RSLV-132 in women with Sjögren's disease to see if it can reduce symptoms like fatigue and dryness. You may join if you've been diagnosed in the last 30 years and have persistent symptoms.
This study tests a new drug called CM336 for people with primary Sjögren's syndrome (an autoimmune disease affecting salivary and tear glands). The drug is designed to help reduce disease activity in patients who haven't responded well to previous treatments.
This study tests an investigational drug called ICP-488 for people with primary Sjögren's syndrome (the main form, not caused by other conditions). The goal is to see if the drug can help control symptoms better than a placebo. Participants must have active disease and stable treatment.
This study tests a new pill called upadacitinib (a JAK inhibitor) for people with active Sjögren's syndrome. It may help reduce dryness, fatigue, and joint pain by calming the immune system.
This study tests a new medicine called ESG206, which targets a protein on immune cells to help control lupus. If you have active lupus, this treatment might help reduce your symptoms.
Hear when a new Primary Sjögren Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.